Sequoia Financial Advisors LLC Purchases 5,137 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Sequoia Financial Advisors LLC boosted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 4.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 110,338 shares of the company’s stock after acquiring an additional 5,137 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $1,152,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in the business. Bank of New York Mellon Corp grew its stake in shares of Teva Pharmaceutical Industries by 1.6% during the first quarter. Bank of New York Mellon Corp now owns 1,875,394 shares of the company’s stock valued at $17,609,000 after buying an additional 28,920 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Teva Pharmaceutical Industries by 12.3% in the first quarter. PNC Financial Services Group Inc. now owns 119,076 shares of the company’s stock worth $1,118,000 after acquiring an additional 13,069 shares during the period. MetLife Investment Management LLC raised its position in shares of Teva Pharmaceutical Industries by 4.7% in the 1st quarter. MetLife Investment Management LLC now owns 95,953 shares of the company’s stock worth $901,000 after acquiring an additional 4,300 shares in the last quarter. BlackRock Inc. lifted its position in Teva Pharmaceutical Industries by 3.7% during the 1st quarter. BlackRock Inc. now owns 41,648,716 shares of the company’s stock valued at $391,081,000 after acquiring an additional 1,494,814 shares during the period. Finally, Great West Life Assurance Co. Can lifted its stake in shares of Teva Pharmaceutical Industries by 4.0% in the first quarter. Great West Life Assurance Co. Can now owns 420,533 shares of the company’s stock worth $4,137,000 after buying an additional 16,134 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TEVA has been the subject of a number of recent research reports. The Goldman Sachs Group boosted their price target on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a research note on Monday, February 5th. Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $12.00 to $19.00 in a report on Monday, February 12th. HSBC assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Monday, December 18th. They set a “buy” rating and a $13.00 price objective for the company. Jefferies Financial Group raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and raised their price objective for the company from $10.00 to $14.00 in a research note on Tuesday, January 23rd. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective on the stock in a research report on Friday, March 8th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus price target of $13.78.

Insider Transactions at Teva Pharmaceutical Industries

In related news, CAO Amir Weiss sold 31,766 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the sale, the chief accounting officer now directly owns 10,676 shares of the company’s stock, valued at approximately $132,062.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Teva Pharmaceutical Industries news, CEO Richard D. Francis sold 74,530 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $13.15, for a total transaction of $980,069.50. Following the transaction, the chief executive officer now directly owns 87,125 shares in the company, valued at $1,145,693.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Amir Weiss sold 31,766 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at $132,062.12. The disclosure for this sale can be found here. Insiders have sold 390,738 shares of company stock valued at $5,132,766 over the last ninety days. Insiders own 0.62% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $13.30 on Friday. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23. Teva Pharmaceutical Industries Limited has a 52 week low of $7.09 and a 52 week high of $14.47. The firm has a 50 day moving average of $13.41 and a 200 day moving average of $11.15.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.73 by $0.25. The business had revenue of $4.46 billion during the quarter, compared to the consensus estimate of $3.97 billion. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. Equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.28 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.